Sidera
Latest round
- Series A
Last raised
- Dec 2025
Total raised
- $109M
Investors
- 4
About Sidera
Sidera, based in Copenhagen, Denmark, specializes in developing transformative therapies for cardiometabolic disorders by leveraging advancements in human genetics to create innovative medications aimed at improving patient outcomes. Founded in Copenhagen, Denmark, Sidera focuses on developing therapies for cardiometabolic diseases. No known pivots or changes in the business strategy have been noted. Sidera specializes in developing transformative cardiometabolic therapies by harnessing advancements in human genetics. The company focuses on creating innovative medications aimed at addressing a range of cardiometabolic disorders, including conditions like diabetes, obesity, and cardiovascular diseases. Sidera's therapeutics are designed to improve patient outcomes by targeting the root causes of these conditions, ultimately enhancing quality of life. The company serves a diverse client base, including healthcare providers, research institutions, and pharmaceutical companies, with its products aimed at markets in North America and Europe.Sidera operates on a business model that includes partnerships with healthcare organizations and pharmaceutical companies for its innovative therapies. The revenue generation occurs through these partnerships, which may include licensing agreements and joint research initiatives, leveraging the company's proprietary technologies. The company's flagship products are anticipated to enter the market through direct channels to health systems and specialized distributors, facilitating streamlined access for healthcare providers and their patients. Specific pricing strategies for the therapies are established during negotiations with partners, ensuring competitive positioning within the cardiometabolic treatment landscape. The company is focused on launching new therapies designed for cardiometabolic conditions, further expanding its reach into North American and European markets. As part of its growth strategy, Sidera aims to develop additional innovative solutions aimed at addressing the needs of patients suffering from these prevalent disorders.
Who invested in Sidera
4 investors across 1 round
See all investors in Sidera
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 8, 2025
Amount
$109M
Investors
Questions about Sidera
Who invested in Sidera?
Sidera has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sidera raised?
Sidera has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Sidera last raise money?
Sidera's most recent round on record is a Series A, in Dec 2025.
What does Sidera do?
Sidera, based in Copenhagen, Denmark, specializes in developing transformative therapies for cardiometabolic disorders by leveraging advancements in human genetics to create innovative medications aimed at improving patient outcomes.
Where is Sidera headquartered?
Sidera is headquartered in Copenhagen, Denmark.
Which VCs invest in companies like Sidera?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Sidera's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Sidera? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.